China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the transition of its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab from conditional approval to full approval for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib or chemotherapy.
Camrelizumab’s Approval History and Indications
Camrelizumab, which received first approval in China on May 2019, has accumulated eight indication approvals, covering a range of cancers including liver cancer, lung cancer, esophageal squamous cell carcinoma (ESCC), nasopharyngeal cancer (NPC), and lymphoma. These indications are all included in the National Reimbursement Drug List (NRDL), which facilitates patient access to this innovative treatment.
Expanding Access to Camrelizumab
The full approval of camrelizumab for advanced HCC marks a significant milestone in expanding access to this potentially life-saving therapy. The drug’s inclusion in the NRDL ensures that it is not only available to patients in need but also financially accessible, as it is covered by national insurance.
